Thomas Jefferson National Accelerator Facility

Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark

Retrieved on: 
Wednesday, October 11, 2023

BERKELEY, Calif. and MAINZ, Germany, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leading molecular genetics diagnostic company focused on early cancer detection, announced today its participation in the upcoming UEG Week.

Key Points: 
  • BERKELEY, Calif. and MAINZ, Germany, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leading molecular genetics diagnostic company focused on early cancer detection, announced today its participation in the upcoming UEG Week.
  • This prominent event, organized by the United European Gastroenterology and scheduled to take place in Copenhagen, Denmark, from October 14th to 17th, serves as a premier platform for discussing the latest advancements and breakthroughs in the field of gastroenterology.
  • Recognized as a key gathering in the field, UEG Week addresses critical issues in gastroenterology, providing an ideal opportunity for Mainz Biomed to engage with international gastroenterologists, oncologists, and stakeholders interested in advancing the early detection of colorectal cancer (CRC).
  • Mainz Biomed team members will be available throughout the event showcasing ColoAlert® the Company’s flagship product, a highly effective and user-friendly at-home detection test for colorectal cancer (CRC).

EQS-News: Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark

Retrieved on: 
Tuesday, October 17, 2023

Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark

Key Points: 
  • Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark
    The issuer is solely responsible for the content of this announcement.
  • Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark
    Mainz Biomed team members will be available throughout the event at the Company’s booth located in Hall C, Stand C3-92
    BERKELEY, US – MAINZ, Germany – October 11, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leading molecular genetics diagnostic company focused on early cancer detection, announced today its participation in the upcoming UEG Week.
  • Recognized as a key gathering in the field, UEG Week addresses critical issues in gastroenterology, providing an ideal opportunity for Mainz Biomed to engage with international gastroenterologists, oncologists, and stakeholders interested in advancing the early detection of colorectal cancer (CRC).
  • Mainz Biomed team members will be available throughout the event showcasing ColoAlert® the Company’s flagship product, a highly effective and user-friendly at-home detection test for colorectal cancer (CRC).

Seminars on Sustainable Solutions from The LYCRA Company

Retrieved on: 
Tuesday, September 12, 2023

The LYCRA Company , a global leader in developing innovative and sustainable fiber and technology solutions for the apparel and personal care industries, announced today that two employees will be presenting at the 62nd Dornbirn Global Fiber Congress (GFC) .

Key Points: 
  • The LYCRA Company , a global leader in developing innovative and sustainable fiber and technology solutions for the apparel and personal care industries, announced today that two employees will be presenting at the 62nd Dornbirn Global Fiber Congress (GFC) .
  • These presentations cover two key initiatives within the roadmap and vision of The LYCRA Company’s Planet Agenda platform and 2030 Sustainability Goals.
  • View the full release here: https://www.businesswire.com/news/home/20230912977470/en/
    The LYCRA Company's Jean Hegedus, director of sustainable business development, will present “Recyclability of Garments with Stretch Fibers: Challenges and Solutions” at the 62nd Dornbirn Global Fiber Congress (GFC).
  • (Photo: Business Wire)
    “Industrially-Compostable LYCRA® Fiber” is being presented in Hall A on September 13 at 2:20 p.m. CEST by Nicholas Kurland, Ph.D., innovation strategy manager at The LYCRA Company.

OFS Showcases TrueLase™ 22/400-915-3kW Optical Fiberat LASER World of PHOTONICS 2023

Retrieved on: 
Monday, June 26, 2023

MUNICH, June 26, 2023 /PRNewswire/ -- LASER World of PHOTONICS, Hall A, Stand #326- OFS, a leading designer, manufacturer, and supplier of innovative fiber optic products is pleased to announce an improved performance TrueLase Yb 22/400-915-3kW, Ytterbium Doped Active Fiber.

Key Points: 
  • MUNICH, June 26, 2023 /PRNewswire/ -- LASER World of PHOTONICS, Hall A, Stand #326- OFS, a leading designer, manufacturer, and supplier of innovative fiber optic products is pleased to announce an improved performance TrueLase Yb 22/400-915-3kW, Ytterbium Doped Active Fiber.
  • OFS will showcase the new fiber at LASER World of PHOTONICS, the world's leading photonics trade fair, being held at the Munich exhibition grounds from June 27 to 30, 2023.
  • Thanks to its compatibility with numerous fibers and components available on the market, the TrueLase Yb 22/400-915-3kW fiber allows laser manufacturers to build their own multi-kW fiber laser cavity's.
  • Phil Familletti, OFS Fiber Laser Product Manager, stated, "With the new TrueLase Yb 22/400-915-3kW double clad fiber, a user pumping using 915nm will be able to achieve over 3KW in a single fiber laser cavity."

At ASCO '23, AI Precision Oncology Company Perthera Unveils Premium Experience for Clinicians with New Options for Ordering and Access to Enhanced Perthera Analytics

Retrieved on: 
Friday, June 2, 2023

As part of this new, enhanced clinician experience, Perthera Lab Direct will make it easier to order reports, delivering results faster and the Perthera RWE Navigator will provide clinicians direct access to Perthera's powerful analytics.

Key Points: 
  • As part of this new, enhanced clinician experience, Perthera Lab Direct will make it easier to order reports, delivering results faster and the Perthera RWE Navigator will provide clinicians direct access to Perthera's powerful analytics.
  • The Category III CPT code provides a critical pathway to reimbursement and wider adoption of AI-assisted Oncology decision support.
  • The new multi-ordering platform and expanded analytics bench are intended to help support increased clinician demand.
  • These resources can be found on Perthera's re-designed website where physicians and their staff can log on to gain access.

Sarah Cannon Research Institute to Present Latest Oncology Research Insights at 2023 ASCO® Annual Meeting

Retrieved on: 
Thursday, June 1, 2023

Sarah Cannon Research Institute (SCRI) announced that its network of research leaders have been selected to deliver insights through more than 135 abstracts and presentations at the 2023 American Society of Clinical Oncology (ASCO®) Annual Meeting June 2-6, 2023.

Key Points: 
  • Sarah Cannon Research Institute (SCRI) announced that its network of research leaders have been selected to deliver insights through more than 135 abstracts and presentations at the 2023 American Society of Clinical Oncology (ASCO®) Annual Meeting June 2-6, 2023.
  • In 2022, SCRI joined together with US Oncology Research as one company to transform oncology research and improve care in more than 24 states across the U.S. Operating as SCRI, the unified research network has over 1,300 physicians enrolling patients to more than 1,000 trials annually.
  • “The collaborations across SCRI’s expanded network are accelerating progress and serving more patients closer to where they live,” says Howard A.
  • “We are looking forward to this year’s Annual Meeting where we will be discussing the results of trials that are advancing therapies across a variety of cancers.”
    For a comprehensive list of abstracts and presentations, click here .

Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Thursday, May 25, 2023

REHOVOT, Israel and MONMOUTH JUNCTION, N.J., May 25, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced updated results from Phase 2 (Part A segment) of the RINGSIDE study evaluating AL102 in desmoid tumors. The results are summarized in an abstract published today for the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. More detailed results will be featured in a poster session at ASCO on Saturday, June 3. AL102 is a once-daily, potent, selective, oral gamma-secretase inhibitor (GSI).

Key Points: 
  • REHOVOT, Israel and MONMOUTH JUNCTION, N.J., May 25, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced updated results from Phase 2 (Part A segment) of the RINGSIDE study evaluating AL102 in desmoid tumors.
  • The results are summarized in an abstract published today for the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • There have been no new safety signals, and the safety results appear consistent with the GSI class.
  • A copy of the poster will be available on the Ayala corporate website, under Events & Presentations, following the presentation at ASCO.

Affini-T Therapeutics to Present AFNT-211 T Cell Product Attributes Targeting KRAS G12V at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Thursday, May 25, 2023

Affini-T Therapeutics, Inc ., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced that preclinical data for its oncogenic driver program targeting KRAS G12V, AFNT–211, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, June 2-6.

Key Points: 
  • Affini-T Therapeutics, Inc ., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced that preclinical data for its oncogenic driver program targeting KRAS G12V, AFNT–211, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, June 2-6.
  • “We are pleased to present novel preclinical data from our cell therapy targeting KRAS G12V, highlighting the robust stemness properties of our cell product as a key aspect of its comprehensive characterization.
  • These findings establish a solid research foundation and support our ongoing effort to advance the program as a potential paradigm-shifting treatment for solid tumors,” said Loïc Vincent, Ph.D., Chief Scientific Officer, Affini-T Therapeutics.
  • “Our IND-enabling studies have demonstrated potent and specific pharmacological action with a rigorous toxicology profile that support the advancement of the AFNT-211 program to the clinic.”

Healthcare Triangle to Participate at HIMSS23 Conference as Guest Speaker for Amazon Web Services

Retrieved on: 
Monday, April 17, 2023

Roy Sookhoo, COO of Healthcare Triangle, commented, “Adopting the public cloud should no longer be viewed as a risk.

Key Points: 
  • Roy Sookhoo, COO of Healthcare Triangle, commented, “Adopting the public cloud should no longer be viewed as a risk.
  • Rather it should be embraced and seen as a welcome change to help modernize organizations.
  • To fuel this digital transformation, our long-time client CalvertHealth leveraged HCTI’s HITRUST-certified public cloud-powered Data EHR Resiliency solution in combination with Amazon Web Services’ AWS Elastic Disaster Recovery and AWS Backup to strengthen their security posture, while improving performance, efficiency, and reliability.
  • We are excited to join our client at the AWS booth at HIMSS23 for an engaging discussion and audience Q&A.”
    HCTI is designated as a “Premier Consulting Partner” and “Top-10 Healthcare Solutions Partner” for AWS.

Recuro Health is Featured Partner with Microsoft, Showcases Digital Medical Home at HIMSS23 Global Conference

Retrieved on: 
Thursday, April 6, 2023

Recuro Health (Recuro), an integrated digital health solutions company that transitions the U.S. healthcare system from a reactive, disease-focused model to a population health, outcomes approach, announces that it will join Microsoft as a featured partner at the upcoming annual HIMSS23 Global Conference .

Key Points: 
  • Recuro Health (Recuro), an integrated digital health solutions company that transitions the U.S. healthcare system from a reactive, disease-focused model to a population health, outcomes approach, announces that it will join Microsoft as a featured partner at the upcoming annual HIMSS23 Global Conference .
  • View the full release here: https://www.businesswire.com/news/home/20230406005447/en/
    Recuro Health to be featured as a Microsoft Partner at HIMSS23, as we showcase our Digital Medical Home™.
  • “Recuro is privileged to be an invited partner of Microsoft during this important event and given the opportunity to present its complete virtual care solution, the Digital Medical Home,” says Gorton.
  • Core services include virtual primary and urgent care, behavioral health, in-home diagnostics/labs, genomic testing and more as a one-stop shop for all health and wellness benefits in a single solution.